Link Between Cancer And Psilocybin: Research On This Palliative Promise
Portfolio Pulse from Lara Goldstein
Sunstone Therapies' Phase 2 study on psilocybin's long-term efficacy in cancer patients with Major Depressive Disorder (MDD) shows promising results. The study used COMPASS Pathways' (NASDAQ:CMPS) synthetic psilocybin. More research is needed to determine the effectiveness of psychedelics in treating anxiety and depression in cancer patients.
May 22, 2023 | 7:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sunstone Therapies' Phase 2 study used COMPASS Pathways' synthetic psilocybin, showing promising results in treating cancer patients with MDD. More research is needed to determine the effectiveness of psychedelics in treating anxiety and depression in cancer patients.
The positive results from Sunstone Therapies' Phase 2 study using COMPASS Pathways' synthetic psilocybin indicate a potential increase in demand for the product. As more research is conducted and if the results continue to be positive, this could lead to increased interest in COMPASS Pathways' psilocybin and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80